Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites

• Status: Completed
• Trial end date: 2014-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to compare the efficacy of Endostar/cisplatin with cisplatin alone or Endostar alone in patients with malignant pleural effusion or ascites.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
• Treatments: Cisplatin; Endostar protein

Criteria

Inclusion Criteria:

• Histological or cytological diagnosis of thoracic or abdominal tumor

• At least medium amount of malignant pleural effusion or ascites

• ECOG Performance Status 0-2

• Life expectancy ≥ 2 months

• Adequate hematologic, cardiac, renal, and hepatic function

• No major surgery within 4 weeks prior to this study

• Written informed consent

Exclusion Criteria:

• Patients with central nervous system (CNS) metastases

• Evidence of bleeding diathesis, serious infection

• Evidence of myocardial infarction, unstable angina or cardiac insufficiency

• Presence of serious COPD and/or respiratory failure

• Allergic to study drug

• Pregnant or lactating women

• Participation in other clinical trials within 30 days prior to this study